Platelet-rich plasma in the treatment of ATFL tears: a randomized, double-blinded, controlled trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900028556

Enrollment

Unknown

Registered

2019-12-27

Start date

2020-01-01

Completion date

Unknown

Last updated

2020-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ATFL tears

Interventions

Experimental group:PRP

Control group:NS

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosis of ATFL tears by medical history, physical examination and imaging examination; 2. Aged 40-60 years; 3. Platelet count > 1.5 x 10^4; 4. The patient is willing to participate in the study and abandon any other accompanying treatments to complete the follow-up and provide complete information.

Exclusion criteria

Exclusion criteria: 1. The ankle has been traumatized or operated; 2. Other diseases of the ankle joint; for example, tumors, autoimmune diseases; 3. Received sodium hyaluronate or hormone injection 3 months before treatment; 4. Blood system disorders (platelet disease, thrombocytopenia, and anemia HB<9); 5. In the process of immunosuppressive or warfarin treatment.

Design outcomes

Primary

Measure	Time frame
modified AOFAS score;ultrasound results;	—

Secondary

Measure	Time frame
subjective satisfaction of the patient;	—

Countries

China

Contacts

Public ContactLIU YAN

West China Hospital, Sichuan University

123315971@qq.com+86 18190030357

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026